RALEIGH, N.C., Oct. 23 /PRNewswire/ -- CLOSURE Medical Corporation
(Nasdaq: CLSR), today said that it intends to release, on October 26, 2000,
financial results for the third quarter and nine months ended September 30,
2000. In conjunction with this release, CLOSURE will host a conference call
that will be broadcast simultaneously over the Internet at 4:00 p.m. EST on
October 26, 2000. The live call and replay can be accessed via the Internet
at http://www.vcall.com .
Separately, CLOSURE also said it has been invited to give a presentation
at 4:25 p.m. at the CIBC Health Care Conference on October 23rd in New York.
CLOSURE Medical Corporation, headquartered in Raleigh, North Carolina,
develops, manufactures, and commercializes medical tissue adhesive products
based on its proprietary cyanoacrylate technology. CLOSURE's nonabsorbable
tissue adhesive products may be used to replace sutures and staples for
certain topical wound closure applications, while its internal tissue adhesive
products can potentially be used for internal wound closure and management.
Currently marketed nonabsorbable tissue adhesive products include
DERMABOND(R)* Topical Skin Adhesive, which is used to replace sutures and
staples for closure of certain lacerations and incisions; OCTYLDENT(R)*
adhesive, which is used as an adjunct in the treatment of adult periodontal
disease; and the NEXABAND(R)* line of topical adhesives, which are used in
veterinary wound closure and management.
This release contains certain forward-looking statements which involve
known and unknown risks, delays, uncertainties or other factors not under the
Company's control which may cause actual results, performance or achievements
of the Company to be materially different from the results, performance, or
other expectations implied by these forward-looking statements. These factors
include, but are not limited to the early stage of commercialization of the
Company products; the progress of its research and development programs for
future products; the need for regulatory approval and effects of governmental
regulation; technological uncertainties; dependence on marketing partners, and
dependence on patents and trade secrets, as well as those detailed in the
Company's Annual Report on Form 10-K for the year ended December 31, 1999
filed with the Securities and Exchange Commission.
SOURCE CLOSURE Medical Corporation
 back to top
Related links:
http://www.vcall.com
CONTACT:
Robert V. Toni, President & CEO, Benny Ward,
CFO, of CLOSURE Medical Corporation, 919-876-7800, or General,
Stuart Z. Levine, Ph.D., Analysts, Cecelia Heer, Media, Deanne
Eagle, of The Financial Relations Board, 212-661-8030
|
